Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic co...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Mol Sci
Asıl Yazarlar: Itatani, Yoshiro, Kawada, Kenji, Yamamoto, Takamasa, Sakai, Yoshiharu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2018
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5979390/
https://ncbi.nlm.nih.gov/pubmed/29670046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19041232
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller